IR@PKUHSC  > 北京大学基础医学院  > 细胞生物学系
学科主题基础医学
Over-Expression of LAPTM4B is Associated With Poor Prognosis and Chemotherapy Resistance in Stages III and IV Epithelial Ovarian Cancer
Yin, Mingzhu1; Li, Cong2; Li, Xia3; Lou, Ge1; Miao, Bing4; Liu, Xiaodong5; Meng, Fanling1; Zhang, Haiyu6; Chen, Xiuwei1; Sun, Meng6; Ling, Qiu7; Zhou, Rouli8
关键词Laptm4b Epithelial Ovarian Carcinoma Chemotherapy Resistance Survival
刊名JOURNAL OF SURGICAL ONCOLOGY
2011-07-01
DOI10.1002/jso.21912
104期:1页:29-36
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Surgery
研究领域[WOS]Oncology ; Surgery
关键词[WOS]HEPATOCELLULAR-CARCINOMA ; OVEREXPRESSION ; SURVIVAL ; PROTEIN ; MARKER
英文摘要

Background: The purpose of this study was to determine whether LAPTM4B over-expression is associated with the prognosis and chemotherapy resistance in patients with stages III and IV epithelial ovarian carcinoma, i.e., patients with peritoneal metastasis or lymph node metastasis of epithelial ovarian carcinoma. Methods: LAPTM4B expression was evaluated in 10 normal ovarian and 113 stages III-IV ovarian carcinomas specimens by Western blotting analyses and immunohistochemistry. Univariate and multivariate analyses were performed to determine the association between LAPTM4B expression and prognosis and the relationship between LAPTM4B over-expression and chemotherapy resistance.

Results: Western blotting analysis demonstrated that LAPTM4B was overexpressed in ovarian cancers, and immunohistochemistry results revealed that 80 patients were LAPTM4B over-expression. The five-year overall survival (OS) rates for patients with high LAPTM4B expression and low LAPTM4B expression were 27.36% and 90.7%, respectively (hazard ratio = 20.611, 95% CI: 5.916-71.808, P < 0.0001). The five-year progression-free survival (PFS) rate was 17.68% for patients in the high-expression group and 84.42% for patients in the low-expression group (hazard ratio = 17.852, 95% CI: 6.31-5.935, P < 0.0001); The presence of chemotherapy resistance was significantly associated with LAPTM4B expression (OR: 36.609, 95% CI: 4.737-282.941, P = 0.0006).

Conclusions: LAPTM4B over-expression is an independent factor in stages III-IV epithelial ovarian carcinoma prognosis and chemotherapy resistance, and it may be an important potential biomarker. J. Surg. Oncol. 2011;104:29-36. (C) 2011 Wiley-Liss, Inc.

语种英语
WOS记录号WOS:000291347600006
引用统计
被引频次:28[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50752
专题北京大学基础医学院_细胞生物学系
作者单位1.Harbin Med Univ, Tumor Hosp, Dept Gynecol Oncol, Harbin 150081, Peoples R China
2.Harbin Med Univ, Tumor Hosp, Dept Pathol, Harbin 150081, Peoples R China
3.Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Harbin, Peoples R China
4.Chinese Med Hosp Harbin, Senior Officials Inpatient Ward, Harbin, Peoples R China
5.Harbin Med Univ, Dept Emergency Traumatol, Affiliated Hosp 2, Harbin 150081, Peoples R China
6.Harbin Med Univ, Dept Biostat, Harbin 150081, Peoples R China
7.Harbin Med Univ, Dept Microbiol, Harbin 150081, Peoples R China
8.Peking Univ, Dept Cell Biol, Sch Basic Med Sci, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Yin, Mingzhu,Li, Cong,Li, Xia,et al. Over-Expression of LAPTM4B is Associated With Poor Prognosis and Chemotherapy Resistance in Stages III and IV Epithelial Ovarian Cancer[J]. JOURNAL OF SURGICAL ONCOLOGY,2011,104(1):29-36.
APA Yin, Mingzhu.,Li, Cong.,Li, Xia.,Lou, Ge.,Miao, Bing.,...&Zhou, Rouli.(2011).Over-Expression of LAPTM4B is Associated With Poor Prognosis and Chemotherapy Resistance in Stages III and IV Epithelial Ovarian Cancer.JOURNAL OF SURGICAL ONCOLOGY,104(1),29-36.
MLA Yin, Mingzhu,et al."Over-Expression of LAPTM4B is Associated With Poor Prognosis and Chemotherapy Resistance in Stages III and IV Epithelial Ovarian Cancer".JOURNAL OF SURGICAL ONCOLOGY 104.1(2011):29-36.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yin, Mingzhu]的文章
[Li, Cong]的文章
[Li, Xia]的文章
百度学术
百度学术中相似的文章
[Yin, Mingzhu]的文章
[Li, Cong]的文章
[Li, Xia]的文章
必应学术
必应学术中相似的文章
[Yin, Mingzhu]的文章
[Li, Cong]的文章
[Li, Xia]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。